An impressive suite of NBCUniversal FAST channels can now be accessed freely on ad-supported video streaming platform TCL Channel
CANBERRA, Australia and WELLINGTON, New Zealand, Dec. 17, 2024 /PRNewswire/ -- TCL and NBCUniversal have announced a new agreement that aims to enhance the entertainment options for TCL viewers in selected regions. This deal marks the first partnership between the two companies, and it introduces a range of iconic NBCUniversal TV shows to audiences in Australia and New Zealand via these branded FAST channels.
Maintaining its stature as the world's second-largest TV brand with a commanding market share of 12.5%, TCL continues to strengthen its position in the global TV market. The company's streaming platform, TCL Channel, has garnered a substantial following of over 24 million users worldwide, offering a diverse array of content to a global audience.
Access Iconic TV Shows on TCL Channel, for free
Viewers in regions such as Australia and New Zealand can now indulge in a selection of beloved classic TV shows on TCL Channel. Fan-favorite reality shows from hit franchises like "The Real Housewives," "Top Chef," and "Million Dollar Listing," as well as early gems like "The Lone Ranger" are also now easily accessible to TCL viewers.
Accessible FAST channels for viewers in Australia and New Zealand:
Shared Enthusiasm and Goals
Both TCL and NBCUniversal have expressed their enthusiasm for the collaboration. Expressing their excitement for the collaboration, Howie Li, General Manager at TCL FFalcon stated, "We are thrilled to partner with NBCUniversal. This marks a starting point, and in the future, we aim to work with NBCUniversal to bring in more content to serve TCL TV users better, while also enhancing our offerings and services for our advertisers."
"We are delighted to partner with TCL and bring NBCU's suite of FAST channels, featuring our iconic drama, sci-fi, reality, and animated kids series to TCL's audiences in Australia, and New Zealand," said Rob Bell, Executive Vice President of Digital Distribution & Global Content Strategy at NBCUniversal Global TV Distribution
How to Get Your TCL Channel App:
About TCL Electronics and TCL Channel
TCL Electronics (1070.HK) is a leading consumer electronics brand and leader in the global television industry. TCL now operates in more than 160 markets around the world. The company specializes in the research, development, and manufacturing of consumer electronics products ranging from TVs, audio, home appliances, mobile devices, smart glasses, commercial displays, and more.
About NBCUniversal Global TV Distribution
NBCUniversal Global TV Distribution is responsible for the licensing and distribution of NBCUniversal product to all forms of television and new media platforms in the U.S., Canada and in over 200 territories internationally. NBCUniversal's content portfolio includes a vast and diverse library of more than 6,500 feature films and 170,000 television episodes, including current and classic titles, non-scripted programming, kids, sports, news, long-form and short-form programming from Universal Pictures, Focus Features, Universal Television, UCP, Universal International Studios, Sky Studios, Universal Television Alternative Studio, NBC Late Night properties, DreamWorks Animation, Telemundo, and more, as well as locally produced content from around the world. Global TV Distribution is a division of Comcast NBCUniversal.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
TCL and NBCUniversal Partner to Expand Entertainment Offerings
HONG KONG, Dec. 17, 2024 /PRNewswire/ -- Great Bay Bio (GBB) is thrilled to announce the successful first close of its Series B financing round. This milestone was achieved with the round led by a syndication of a well-known strategic investment institution and its affiliate, Tiger Jade Pebble Accelerator. The financing also attracted participation from new investors, including a Hong Kong-based family office, the Hong Kong Science and Technology Parks Venture Fund, as well as continued support from an existing global life science strategic investor. The funds will be instrumental in advancing GBB's AI-enabled drug development ecosystem and accelerating the global adoption of its innovative solutions. This marks a significant step forward in transforming biologics development on an international scale.
GBB's commercialization efforts have been gaining momentum, fueled by technical breakthroughs and market-driven solutions. In the cell line development business, GBB's site-specific cell line development platform, AlfaCell, has enabled customers to secure clinical trial approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). These cell lines have also been successfully applied in multiple projects, with partners expressing satisfaction with improved yields and shorter development timelines, especially for multi-specific antibodies. Additionally, GBB has enhanced its cell culture capabilities by establishing its own ISO 9001:2015-certified cell culture powder manufacturing line, further ensuring a high-quality and secure supply chain for partners. These achievements have positioned GBB as a trusted partner for leading MNCs in the life sciences, specialty chemicals, and pharmaceutical CDMO sectors, meeting the global demand for faster and more efficient new product development.
Building on this foundation, GBB has recently launched an integrated ecosystem solution, combining its advanced technological platforms into a seamless workflow. This innovation enables customers to accelerate drug development from target identification to pre-clinical candidate (PCC) generation in as little as eight months. While GBB has just started collaboration with partners using this approach, early results are promising and highlight its potential to redefine efficiency and speed in drug development, delivering significant value to global partners.
Kingsley Leung, Co-founder and Chairman of GBB, commented: "GBB was founded with a global vision, and our benchmark for success has always been to develop technologies that are globally differentiated. We are confident in our ability to continue building an international footprint, particularly across the U.S., Europe, and Asia-Pacific, where we see significant opportunities for growth. The strong support from our series B investors reflects their trust in our vision and reinforces our commitment to driving innovation that transforms the biopharmaceutical industry worldwide."
Emmanuel Hui, CEO of the Tiger Jade Pebble Accelerator added: "The biggest challenges for applying AI in the biomedical space are scientific feedback and business model fit. Innovators often don't know whether or not their AI products work until after extensive animal and human testing, and even then, it is unclear who would be the paying party. GBB's deliberate strengths in cell line, culture media, and bioprocessing veer away from general AI drug discovery, and allows for immediate feedback, iteration, and client payment."
About GBB
Great Bay Bio (GBB), headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of "Global Bioprocessing Made Simpler and More Efficient," and aims to address the challenges of long timelines, high costs, and low success rates in drug development, with a long-term goal of enhancing human life, health, and value.
The core team of GBB comprises experts from medicine, synthetic biology, and artificial intelligence. The company operates a 3,000㎡ R&D laboratory and CMC platform, supporting customers in securing clinical trial approvals from China's NMPA and the US FDA. GBB has secured nearly 100 patents related to AI-enabled drug development and successfully commercialized multiple AI technology platforms. The company has established long-term partnerships with leading domestic and international enterprises.
GBB has passed the ISO 9001:2015 quality management system certification, been selected for Forbes Asia 100 to Watch 2024 List, and won numerous awards, including "Deloitte Technology Rising Star Company," "EY Entrepreneur Of The Year," "15th Shenzhen Innovation & Entrepreneurship Competition," "Gold Award for Hong Kong Global Innovation," "Excellence in Process Innovation Award," and "Excellence in Technology Adoption Award". The company has also been successfully selected for the Hong Kong Science Park Elite Enterprise Program.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Great Bay Bio Completes First Close of Series B Financing
